Flare frequency and duration in patients with generalized pustular psoriasis (GPP)

Denis Jullien1, Azura Mohd Affandi1, Laurent Misery2, Tang Jyh Jong3, Hamida Turki5, Pubalan Muniandy6, Tan Wooi Chiang2

1. Department of Dermatology, Hacettepe University Hospital, Ankara, Turkey; 2. Department of Dermatology, Hôtel-Dieu de Strasbourg Hospital, Strasbourg, France; 3. Department of Dermatology, National Skin Center, Kuala Lumpur, Malaysia; 4. Department of Dermatology, University Hospital of Besançon, Besançon, France; 5. Department of Dermatology, Hedi Chaker Hospital, University of Sfax, Sfax, Tunisia; 6. Department of Dermatology, Hospital Pulau Pinang, Pulau Pinang, Malaysia

INTRODUCTION
To characterize the frequency, number, and duration of flares in patients with GPP.

AIM
Flare episodes are a heavy burden for patients with GPP, and there is a need for more effective treatment options.

METHODS
• We conducted a retrospective chart review including patients with GPP.
  • The mean (SD) follow-up duration was 5.0 (3.1) years.

RESULTS
• The mean (SD) duration of flares was 34.3 (41.2) days during follow-up.
• Overall, 47% of patients experienced ≥1 flare episode since diagnosis.

CONCLUSIONS
• Flare episodes are a heavy burden for patients with GPP.
• The severity of acute episodes and burden of chronic flares demonstrate the need for more effective treatment options.

Flare episodes and hospitalization

Overall, 47% of patients experienced ≥1 flare, and more than 37% of patients experienced at least 1 hospitalization since diagnosis.

Follow-up visit type

Flare-related hospitalization

The mean (SD) duration between flare-related hospitalizations was 14.1 (17.4) months.

Percentage (%) of patients with ≥1 flare episode and ≥1 hospitalizations since diagnosis.

<table>
<thead>
<tr>
<th>Country</th>
<th>France (N=103)</th>
<th>Malaysia (N=55)</th>
<th>Tunisia (N=17)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No flares</td>
<td>92 (52.4)</td>
<td>62 (60.2)</td>
<td>25 (45.5)</td>
</tr>
<tr>
<td>At least 1 flare</td>
<td>51 (47.6)</td>
<td>33 (39.8)</td>
<td>30 (54.5)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Country</th>
<th>France (N=103)</th>
<th>Malaysia (N=55)</th>
<th>Tunisia (N=17)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No flare-related hospitalizations</td>
<td>109 (62.3)</td>
<td>69 (67.0)</td>
<td>34 (61.8)</td>
</tr>
<tr>
<td>At least 1 flare-related hospitalizations</td>
<td>36 (35.0)</td>
<td>14 (25.5)</td>
<td>9 (52.9)</td>
</tr>
</tbody>
</table>

Follow-up visits.

Patients had an average of 2 flares per year (mean (SD) 2.33 (1.16)).

**Adverse events**

- Flare-related care was the second most common reason for patient visits, exposed only by routine follow-up.

**Complications**

- The mean (SD) duration of flares was 34.3 (41.2) days during follow-up.

**Comorbidities**

- Overall, 47% of patients experienced ≥1 flare, and more than 37% of patients experienced at least 1 hospitalization since diagnosis.

**Efficacy**

- Week 12 data from PoCC study.

**Adverse events**

- The mean (SD) duration between flare-related hospitalizations was 14.1 (17.4) months.

**Comorbidities**

- Approximately half of hospitalizations were flare-related, and the mean duration of flare-related admissions was similar to that of non-flare admissions.

**Efficacy**

- Week 12 data from PoCC study.

**Adverse events**

- The mean (SD) duration between flare-related hospitalizations was 14.1 (17.4) months.

**Comorbidities**

- Approximately half of hospitalizations were flare-related, and the mean duration of flare-related admissions was similar to that of non-flare admissions.

**Efficacy**

- Week 12 data from PoCC study.

**Adverse events**

- The mean (SD) duration between flare-related hospitalizations was 14.1 (17.4) months.

**Comorbidities**

- Approximately half of hospitalizations were flare-related, and the mean duration of flare-related admissions was similar to that of non-flare admissions.

**Efficacy**

- Week 12 data from PoCC study.

**Adverse events**

- The mean (SD) duration between flare-related hospitalizations was 14.1 (17.4) months.

**Comorbidities**

- Approximately half of hospitalizations were flare-related, and the mean duration of flare-related admissions was similar to that of non-flare admissions.